Vanibiss Butt and Thighs

Description

BUTT & THIGHS ACNE TREATMENT CREAM is formulated for the targeted treatment of acne in the buttock and thigh areas. The product is designed to address acne lesions effectively, promoting clearer skin. The formulation is intended for topical application and is suitable for use on affected areas.

The cream is packaged in a convenient dosage form, ensuring ease of application. The specific composition and inactive ingredients are tailored to enhance the efficacy of the active components while maintaining skin compatibility.

This treatment is effective as of November 2, 2023, and is intended for individuals seeking a specialized solution for acne in localized regions.

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals are advised to ensure that the skin is thoroughly cleaned prior to the application of the product. The affected area should be covered with a thin layer of the product, applied one to three times daily.

Initial treatment should begin with one application per day. Based on the patient's response and as directed by a physician, the frequency may be gradually increased to two or three times daily.

In cases where bothersome dryness or peeling occurs, it is recommended to reduce the application frequency to once daily or every other day to mitigate these effects.

Contraindications

There are no specific contraindications identified for this product. However, it is advised to discontinue use and consult a healthcare professional if the condition worsens or does not improve with regular use as directed. Additionally, the concurrent use of this product with other topical acne medications may increase the risk of skin irritation and dryness. Therefore, if irritation occurs, it is recommended to use only one topical acne medication at a time.

Warnings and Precautions

This product is intended for external use only. It is imperative that healthcare professionals advise patients against using this product on children under 12 years of age unless specifically directed by a physician.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients should be instructed to discontinue use and consult a healthcare provider if their condition worsens or fails to improve with regular application of the product as directed. Monitoring for these signs is essential to ensure patient safety and effective treatment outcomes.

Side Effects

Patients should be aware that the product is for external use only and should not be applied to children under 12 years of age unless directed by a doctor.

In the event that the condition worsens or does not improve with regular use of this product as directed, patients are advised to stop use and consult a doctor.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications should be considered to alleviate symptoms. Monitoring for signs of skin irritation is recommended when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Vanibiss Butt and Thighs (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this medication unless directed by a healthcare professional. Caution is advised when considering treatment in this age group, and appropriate medical guidance is essential to ensure safety and efficacy.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the potential for altered pharmacokinetics and pharmacodynamics in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of data does not preclude the need for careful evaluation and monitoring based on individual patient circumstances.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

There is currently no available information regarding teratogenic effects. Similarly, no data has been provided concerning non-teratogenic effects. The nonclinical toxicology section lacks any specific information, and there are no details available related to animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important for patients to understand the potential risks associated with ingestion and the need for prompt action.

Patients should be instructed to discontinue use of the product and consult a healthcare professional if their condition worsens or does not improve with regular use as directed. This guidance is crucial to ensure that patients are aware of the importance of monitoring their symptoms and seeking further evaluation if necessary.

Additionally, healthcare providers should inform patients that skin irritation and dryness may be more likely to occur if they are using another topical acne medication concurrently. Patients should be cautioned to use only one topical acne medication at a time to minimize the risk of irritation. This information is essential for helping patients manage their treatment effectively and avoid adverse effects.

Storage and Handling

The product is supplied in a tube, with the lot number and expiration date clearly indicated on the top of the container. It is essential to protect the product from excessive heat and direct sunlight to maintain its integrity and efficacy. Proper storage conditions should be observed to ensure optimal performance.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Vanibiss Butt and Thighs, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)